Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd(The Ohio State University), Susan O’Brien(University of California, Irvine), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Richard R. Furman(Cornell University), Steven Coutré(Georgetown University), Fong Clow(Pharmacyclics (United States)), Amy J. Johnson(Ouranos), Eric Hedrick(Florida Hospital Cancer Institute), Kristie A. Blum(Emory University), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Betty Chang(Rigel (United States)), Joseph J. Buggy(Pharmacyclics (United States)), Weiqiang Zhao(Harbin Institute of Technology), Danelle F. James(Pharmacyclics (United States)), Morton Coleman(Cornell University), William G. Wierda(University of Maryland, Baltimore), Jeffrey A. Jones(The Ohio State University), Nyla A. Heerema(The Ohio State University), Ian W. Flinn(Tennessee Oncology), Barbara Grant(University of Vermont), Juthamas Sukbuntherng(Pharmacyclics (United States))
Cited by 2,249
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k